| Jason M Johanning, MD | |
|
988102 Nebraska Medical Ctr, Omaha, NE 68198-8102 | |
| (402) 559-7300 | |
| (402) 559-8985 |
| Full Name | Jason M Johanning |
|---|---|
| Gender | Male |
| Speciality | Vascular Surgery |
| Experience | 30 Years |
| Location | 988102 Nebraska Medical Ctr, Omaha, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215985791 | NPI | - | NPPES |
| 47078557580 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0129X | Surgery - Vascular Surgery | 21894 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unmc Physicians | 6002728391 | 1320 |
News Archive
Gilead Sciences, Inc. today announced that, in consultation with the U.S. Food and Drug Administration (FDA), the company will amend the design of ongoing clinical trials to discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.
In this post in Huffington Post's "Healthy Living" blog, John-Manuel Andriote, a journalist and author living with HIV, asks, "For all of us living with HIV infection - Oct. 27 will mark seven years since my own diagnosis - the question we face daily, hopefully more consciously and deliberately than most, is how shall we live, knowing as we do that we will most assuredly die one day?"
Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.
Chemists at the California Institute of Technology (Caltech) and The Scripps Research Institute (SRI) have developed an innovative technique to create cheap but highly stable chemicals that have the potential to take the place of the antibodies used in many standard medical diagnostic tests. James R. Heath, Ph.D., principal investigator of the Nanosystems Biology Cancer Center at Caltech, one of eight Centers of Cancer Nanotechnology Excellence, and K. Barry Sharpless, Ph.D., SRI, and their colleagues describe the new technique in the journal Angewandte Chemie International Edition.
Doctors have urged hospitals around the world to reconsider the type of fluids used to treat children gravely ill with sepsis.
› Verified 4 days ago
| Entity Name | Unmc Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417912114 PECOS PAC ID: 6002728391 Enrollment ID: O20031104000664 |
News Archive
Gilead Sciences, Inc. today announced that, in consultation with the U.S. Food and Drug Administration (FDA), the company will amend the design of ongoing clinical trials to discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.
In this post in Huffington Post's "Healthy Living" blog, John-Manuel Andriote, a journalist and author living with HIV, asks, "For all of us living with HIV infection - Oct. 27 will mark seven years since my own diagnosis - the question we face daily, hopefully more consciously and deliberately than most, is how shall we live, knowing as we do that we will most assuredly die one day?"
Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.
Chemists at the California Institute of Technology (Caltech) and The Scripps Research Institute (SRI) have developed an innovative technique to create cheap but highly stable chemicals that have the potential to take the place of the antibodies used in many standard medical diagnostic tests. James R. Heath, Ph.D., principal investigator of the Nanosystems Biology Cancer Center at Caltech, one of eight Centers of Cancer Nanotechnology Excellence, and K. Barry Sharpless, Ph.D., SRI, and their colleagues describe the new technique in the journal Angewandte Chemie International Edition.
Doctors have urged hospitals around the world to reconsider the type of fluids used to treat children gravely ill with sepsis.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason M Johanning, MD 988102 Nebraska Medical Ctr, Omaha, NE 68198-8102 Ph: (402) 559-7300 | Jason M Johanning, MD 988102 Nebraska Medical Ctr, Omaha, NE 68198-8102 Ph: (402) 559-7300 |
News Archive
Gilead Sciences, Inc. today announced that, in consultation with the U.S. Food and Drug Administration (FDA), the company will amend the design of ongoing clinical trials to discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.
In this post in Huffington Post's "Healthy Living" blog, John-Manuel Andriote, a journalist and author living with HIV, asks, "For all of us living with HIV infection - Oct. 27 will mark seven years since my own diagnosis - the question we face daily, hopefully more consciously and deliberately than most, is how shall we live, knowing as we do that we will most assuredly die one day?"
Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.
Chemists at the California Institute of Technology (Caltech) and The Scripps Research Institute (SRI) have developed an innovative technique to create cheap but highly stable chemicals that have the potential to take the place of the antibodies used in many standard medical diagnostic tests. James R. Heath, Ph.D., principal investigator of the Nanosystems Biology Cancer Center at Caltech, one of eight Centers of Cancer Nanotechnology Excellence, and K. Barry Sharpless, Ph.D., SRI, and their colleagues describe the new technique in the journal Angewandte Chemie International Edition.
Doctors have urged hospitals around the world to reconsider the type of fluids used to treat children gravely ill with sepsis.
› Verified 4 days ago
Bradley Hall, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 42 Nd And Emile Street Univ Of Nebraska Ctr, Department Of General Surgery, Omaha, NE 68198 Phone: 402-559-4300 Fax: 402-559-6749 | |
Dr. Brett Waibel, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: Emile @ 42nd St, Omaha, NE 68198 Phone: 402-559-4017 | |
Dr. Alan T. Richards, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 8303 Dodge St, Suite # 304, Omaha, NE 68114 Phone: 402-354-5048 Fax: 402-354-2585 | |
Dr. Abbey Fingeret, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: Emile 42nd St, Omaha, NE 68198 Phone: 402-559-5600 Fax: 402-559-7900 | |
Dr. John Moonkeun Park, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 515 N 162nd Ave, Ste. 300, Omaha, NE 68118 Phone: 402-393-6624 Fax: 402-393-6635 | |
Dr. John Francis Tierney Iv, MD Surgery Medicare: Medicare Enrolled Practice Location: 988102 Nebraska Medical Ctr, Omaha, NE 68198 Phone: 402-559-6111 | |
Matthew Dale, MD, PHD Surgery Medicare: Medicare Enrolled Practice Location: 7710 Mercy Rd Ste 202, Omaha, NE 68124 Phone: 402-717-4900 |